Loading organizations...
Chione Ltd operates as a private global investment holding company, deploying capital into diverse private and public investments. Its portfolio spans leisure, hospitality, medical research, real estate, and entertainment. The firm prioritizes long-term value creation through meticulous selection, partnering with global service providers to manage varied interests.
Specific founders or an inception date are not publicly detailed. Nevertheless, Chione Ltd maintains an established global operational footprint, guided by insight into diversified, patiently managed capital. This approach reflects a commitment to integrity and a clear strategic vision across numerous asset classes.
As an investment holding entity, Chione Ltd focuses on strategic growth and performance of its portfolio companies. The firm aims to foster stability and achieve financial objectives through astute capital allocation and active oversight. Its vision is to reinforce its standing as a discerning global investor, expanding holdings and optimizing returns.
Chione has 2 tracked investments across 2 companies. The latest tracked deal is $36.0M Series D in Sera Prognostics in November 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 13, 2019 | Sera Prognostics | $36.0M Series D | Charles Kennedy | Catalyst Health Ventures, Domain Associates, Interwest Partners, Labcorp |
| Nov 2, 2011 | Karyopharm Therapeutics Inc. | $10.0M Series A | Chione | — |